COVID-19 vaccination in patients with immunity-mediated kidney disease

Vaccination against SARS-CoV-2 seems to be safe in patients with immunity-mediated kidney disease, although their immunological responses to vaccination are impaired. Further strategies, including the administration of additional vaccine doses and passive immunization with long-acting monoclonal ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Prendecki, Maria, Willicombe, Michelle, McAdoo, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525453/
https://www.ncbi.nlm.nih.gov/pubmed/34667284
http://dx.doi.org/10.1038/s41581-021-00502-7
_version_ 1784585689516474368
author Prendecki, Maria
Willicombe, Michelle
McAdoo, Stephen P.
author_facet Prendecki, Maria
Willicombe, Michelle
McAdoo, Stephen P.
author_sort Prendecki, Maria
collection PubMed
description Vaccination against SARS-CoV-2 seems to be safe in patients with immunity-mediated kidney disease, although their immunological responses to vaccination are impaired. Further strategies, including the administration of additional vaccine doses and passive immunization with long-acting monoclonal antibodies, might increase protection in this vulnerable patient group.
format Online
Article
Text
id pubmed-8525453
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-85254532021-10-20 COVID-19 vaccination in patients with immunity-mediated kidney disease Prendecki, Maria Willicombe, Michelle McAdoo, Stephen P. Nat Rev Nephrol Comment Vaccination against SARS-CoV-2 seems to be safe in patients with immunity-mediated kidney disease, although their immunological responses to vaccination are impaired. Further strategies, including the administration of additional vaccine doses and passive immunization with long-acting monoclonal antibodies, might increase protection in this vulnerable patient group. Nature Publishing Group UK 2021-10-19 2021 /pmc/articles/PMC8525453/ /pubmed/34667284 http://dx.doi.org/10.1038/s41581-021-00502-7 Text en © Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Comment
Prendecki, Maria
Willicombe, Michelle
McAdoo, Stephen P.
COVID-19 vaccination in patients with immunity-mediated kidney disease
title COVID-19 vaccination in patients with immunity-mediated kidney disease
title_full COVID-19 vaccination in patients with immunity-mediated kidney disease
title_fullStr COVID-19 vaccination in patients with immunity-mediated kidney disease
title_full_unstemmed COVID-19 vaccination in patients with immunity-mediated kidney disease
title_short COVID-19 vaccination in patients with immunity-mediated kidney disease
title_sort covid-19 vaccination in patients with immunity-mediated kidney disease
topic Comment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525453/
https://www.ncbi.nlm.nih.gov/pubmed/34667284
http://dx.doi.org/10.1038/s41581-021-00502-7
work_keys_str_mv AT prendeckimaria covid19vaccinationinpatientswithimmunitymediatedkidneydisease
AT willicombemichelle covid19vaccinationinpatientswithimmunitymediatedkidneydisease
AT mcadoostephenp covid19vaccinationinpatientswithimmunitymediatedkidneydisease

Ejemplares similares